SuperBAC Biotechnology Solutions

bti-biotechnologyinstitute.com

Founded in 1995, SuperBAC is a biotechnology solutions company, with the objective of promoting sustainability in the productive processes of agribusiness, sanitation, energy, bioremediation and retail. With manufacturing units and research and development centers in Brazil, the United States and Colombia, its main objective is to create environmentally correct and economically viable alternatives that contribute decisively to the sustainable development of the planet. SuperBAC advocates the introduction of the biotechnological platform for the sustainable development of the planet. SuperBAC is a Biotechnology company established in 1995 focused on providing sustainable products and solutions in agribusiness, sanitation, oil & gas, bioremediation and retail.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

news image

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More

Industrial Impact

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More

Cell and Gene Therapy

PHYTOLON AND GINKGO BIOWORKS COLLABORATE TO TAKE BIOLOGICAL PRODUCTION OF VIBRANT FOOD COLORS TO THE NEXT LEVEL

Phytolon; Ginkgo Bioworks | February 28, 2022

news image

Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to ...

Read More

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

news image

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More
news image

Cell and Gene Therapy

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More
news image

Industrial Impact

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

Cell and Gene Therapy

PHYTOLON AND GINKGO BIOWORKS COLLABORATE TO TAKE BIOLOGICAL PRODUCTION OF VIBRANT FOOD COLORS TO THE NEXT LEVEL

Phytolon; Ginkgo Bioworks | February 28, 2022

Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to ...

Read More
news image

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us